H.C. Wainwright reiterates Buy rating on Monopar stock at $125

H.C. Wainwright reiterated a Buy rating and $125 price target for Monopar Therapeutics (MNPR) as it nears completion of its NDA submission for ALXN1840 in Wilson Disease. The stock trades at $68.05, with a Strong Buy consensus. Clinical data shows improvements in copper balance and neurological symptoms. The company has a strong balance sheet, with a current ratio of 33.56. BTIG raised its target to $133, while Cantor Fitzgerald downgraded to Neutral with a $119 target.

Original reporting
Published Nov 12, 2026, 5:16 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 12, 2026, 5:28 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$MNPR
Bullish
medium confidence
Mentioned
$MNPR
Relevance
4/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$MNPRBullishLow
01

Why it matters

Analyst reiteration may attract short‑term buying but the core clinical milestone has been previously disclosed.

02

Market read

Modest relevance; primarily an analyst opinion piece with limited new material.

03

What to watch

Potential regulatory delays or competitive therapies could temper upside despite the analyst's optimism.

Relevance 4/10Novelty 2/10Timing: none

Background

Monopar Therapeutics is advancing its ALXN1840 NDA for Wilson Disease; multiple analysts have issued ratings and targets.

Company-level read

Ticker impact

$MNPRBullishMedium confidence
Context

H.C. Wainwright reiterated a Buy rating and raised the price target to $125 for Monopar Therapeutics (MNPR) while the stock trades around $68.

Expected impact

potential upward pressure as investors price in the $125 target versus current levels

Evidence & confidence

The rating and target are new in this article, but the underlying NDA progress has been reported previously, limiting the catalyst strength.

Market effects

Limited; reinforces positive sentiment in the rare‑disease biotech niche.

None

Low

Counterpoint

The stock may already be fully priced for the NDA progress; the higher target may not translate into near‑term price gains.

Key entities

  • Monopar Therapeutics

    Biotech firm developing ALXN1840 for Wilson Disease.

  • H.C. Wainwright

    Equity research firm that issued the Buy rating.

Related articles

$MNPRMed

Monopar Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Updates

Monopar Therapeutics (MNPR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Monopar Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Updates Wilmette, IL, November 12, 2026 – Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical‐stage biopharmaceutical company developing innovative t

$MNPRMedAI 8/10

Monopar presents Wilson disease trial data at liver conference

Monopar Therapeutics (MNPR) presented Phase 3 FoCus trial data for Wilson disease at a liver conference. Key findings include high rates of cirrhosis, neurologic, and psychiatric symptoms among patients. ALXN1840, its investigational therapy, showed positive long-term data. The trial is the largest randomized controlled study in Wilson disease.

$MNPRMedAI 8/10

Monopar Presents Data Highlighting Residual Disease Burden in Treatment-Experienced Wilson Disease Patients and Long-Term Molybdenum Safety Data for ALXN1840 at AASLD – The Liver Meeting® 2026

Monopar Therapeutics (MNPR) presented data from its Phase 3 FoCus trial at AASLD 2026, showing significant disease burden in Wilson disease patients, including cirrhosis, neurologic, and psychiatric symptoms. ALXN1840, Monopar's investigational therapy, demonstrated long-term safety with neutral molybdenum balance and normal uric acid levels over six years.

$MNPRLow

Monopar Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates

Monopar Therapeutics (MNPR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Monopar Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates Wilmette, IL, August 12, 2026 – Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical‐stage biopharmaceutical company developing innovative tr

$MNPRMedAI 8/10

Monopar Presents Phase 2 ALXN1840 Data Demonstrating Liver Disease Stabilization and Neurologic Improvement in Treatment-Experienced Wilson Disease Patients at EASL 2026

Monopar Therapeutics presented Phase 2 ALXN1840 (tiomolibdate choline) data at EASL 2026 for treatment-experienced Wilson disease patients. In an open-label, multicenter 48-week trial (29 patients; 24 with paired biopsies), histology showed stabilization or improvement in multiple liver measures, with no statistically significant change in hepatic copper. The company also reported significant improvements in UWDRS Part III, CGI, and EQ-5D UK, with generally nonserious Grade 1–2 adverse events.